Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Schettler

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Atherosclerosis. Supplements|December 11, 2019
Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresisReinhard Klingel, Franz Heigl, Volker Schettler, et al.
Advances in Therapy|January 29, 2024
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS StudyMichael Lehrke, Anja Vogt, Volker Schettler, et al.
Atherosclerosis. Supplements|November 4, 2017
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolismFranz Heigl, Tobias Pflederer, Volker Schettler, et al.
Atherosclerosis. Supplements|November 4, 2017
Efficacy of lipid reduction with DALI and MONETWolfgang Ramlow, Eberhard Röseler, Franz Heigl, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|April 26, 2013
Body weight telemetry is useful to reduce interdialytic weight gain in patients with end-stage renal failure on hemodialysisClaas L Neumann, Fabian Wagner, Jan Menne, et al.
Atherosclerosis. Supplements|November 4, 2017
Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational studyJustyna Kozik-Jaromin, Eberhard Röseler, Franz Heigl, et al.
European Heart Journal|February 21, 2026
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trialKlaus G Parhofer, Ulrich Julius, Anna Laura Herzog, et al.
European Heart Journal|August 31, 2016
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Atherosclerosis. Supplements|December 11, 2019
Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresisReinhard Klingel, Franz Heigl, Volker Schettler, et al.
Advances in Therapy|January 29, 2024
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS StudyMichael Lehrke, Anja Vogt, Volker Schettler, et al.
Atherosclerosis. Supplements|November 4, 2017
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolismFranz Heigl, Tobias Pflederer, Volker Schettler, et al.
Atherosclerosis. Supplements|November 4, 2017
Efficacy of lipid reduction with DALI and MONETWolfgang Ramlow, Eberhard Röseler, Franz Heigl, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|April 26, 2013
Body weight telemetry is useful to reduce interdialytic weight gain in patients with end-stage renal failure on hemodialysisClaas L Neumann, Fabian Wagner, Jan Menne, et al.
Atherosclerosis. Supplements|November 4, 2017
Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational studyJustyna Kozik-Jaromin, Eberhard Röseler, Franz Heigl, et al.
European Heart Journal|February 21, 2026
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trialKlaus G Parhofer, Ulrich Julius, Anna Laura Herzog, et al.
European Heart Journal|August 31, 2016
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Pageof 2